Product Data Sheet

Loteprednol Etabonate

Cat. No.: HY-17358

CAS No.: 82034-46-6

Molecular Formula: $C_{24}H_{31}ClO_7$ Molecular Weight: 466.95

Target: Glucocorticoid Receptor; Bacterial; Antibiotic

Pathway: Immunology/Inflammation; Vitamin D Related/Nuclear Receptor; Anti-infection

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

SOLVENT & SOLUBILITY

In Vitro DMSO: 100 mg/mL (214.16 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1416 mL	10.7078 mL	21.4156 mL
	5 mM	0.4283 mL	2.1416 mL	4.2831 mL
	10 mM	0.2142 mL	1.0708 mL	2.1416 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Loteprednol etabonate (LE) is an orally active "soft" steroid belonging to a unique class of glucocorticoids. Loteprednol etabonate (LE) exhibits anti-inflammatory activity and has been used in optometry and ophthalmology ^{[1][2][3]} .
In Vivo	Intravenous administration of Loteprednol etabonate (5 mg/kg) to dogs reveals a terminal half-life of 2.8 h, a volume of distribution of 3.7 L/kg, and a total body clearance of 0.9 L/h/kg. Intact loteprednol etabonate was not detectable in the urine. After oral administration of the drug (5 mg/kg) to dogs, only metabolites, but no intact drug, were found in the plasma, an indication for a high first-pass effect. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Noble S, Goa KL. Loteprednol etabonate: clinical potential in the management of ocular inflammation. BioDrugs. 1998 Oct;10(4):329-39.
- [2]. Szelenyi I, Hochhaus G, Heer S et al. Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20
- [3]. Howes JF. Loteprednol etabonate: a review of ophthalmic clinical studies. Pharmazie. 2000 Mar;55(3):178-83.
- [4]. Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008 Apr;92(4):455-9.
- [5]. Comstock TL, Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. 2012;2012:789623.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com